                     AIDS Daily Summary
                      November 23, 1994

The Centers for Disease Control and Prevention (CDC) National AIDS
Clearinghouse makes available the following information as a public
service only. Providing this information does not constitute endorsement
by the CDC, the CDC Clearinghouse, or any other organization. Reproduction
of this text is encouraged; however, copies may not be sold, and the CDC
Clearinghouse should be cited as the source of this information.
Copyright 1994, Information, Inc., Bethesda, MD


************************************************************
"AZT Patent Ruling"
"Critics Question BioChem Surge"
"Judge: Doctor Failed to Aid AIDS Patient"
"Liposome Technology's DOX-SL Drug Shown to Be Efficacious in 
Treating AIDS Patients with Advanced Kaposi's Sarcoma; Liposome 
Technology Clinical Investigators Present Clinical Trial Data at 
Glasgow AIDS Meeting"
"Genesis House and Mercy Hospital to Hold 'Vigil Mass of Hope' to
Highlight World AIDS Day"
"Tennis--Chris and Martina to Reunite for 1995 Legends Tour"
"Behavioral Science in the AIDS Epidemic"
"Efficient Neutralization of Primary Isolates of HIV-1 by a 
ecombinant Human Monoclonal Antibody"
"Red Hot+New"
"A Cluster of Tuberculosis among Crack House Contacts in San 
Mateo County, California"
*************************************************************

"AZT Patent Ruling"
Wall Street Journal (11/23/94) P. B4
     The U.S. Court of Appeals has upheld most of a previous ruling 
awarding exclusive patents for AZT to Burroughs Wellcome Co.  The
court ruled that Burroughs was the sole inventor for five out of 
six patents because it conceived of using the drug on AIDS 
patients before obtaining the results of early tests.  The court 
opinion stated that the same decision could not be made for the 
sixth patent without a trial.   The patents were challenged by 
Barr Laboratories Inc. and Novapharm Inc., who argued that tests 
by the National Institutes of Health were instrumental in AZT's 
development and promised to charge less for the drug if they won.
      
"Critics Question BioChem Surge"
Toronto Globe and Mail (11/23/94) P. B1
     Many analysts reacted skeptically to the surge in BioChem Pharm 
Inc. stock on Tuesday, following the announcement of successful 
test results for its AIDS drug 3TC.  Yorkton Securities Inc. 
issued a report stating, "Popular press overreacts," and pointing
out that three other AIDS drugs for use with AZT have already 
been approved.  3TC is still  undergoing testing in North America
and has not yet received regulatory approval for the treatment of
AIDS.  Martin Sherwood, a spokesman for Wellcome PLC, which has a
non-binding deal with Glaxo for development and marketing rights 
to 3TC, said that Wellcome has patent claims for the drug's HIV 
and hepatitis B applications
      
"Judge: Doctor Failed to Aid AIDS Patient"
Chicago Tribune (11/22/94) P. 1-4
     A U.S. District Judge has ruled that a doctor violated the 
Americans With Disabilities Act when he refused to treat a man at
a hospital because he had AIDS.  Fred Charon went to Memorial 
Hospital in Fremont, Ohio, in April 1992 because of a fever and 
other symptoms, but was refused admittance and taken 45 miles 
away to a Toledo hospital.  A spokesman for the hospital says the
ruling will be appealed.
      
"Liposome Technology's DOX-SL Drug Shown to Be Efficacious in 
Treating AIDS Patients with Advanced Kaposi's Sarcoma; Liposome 
Technology Clinical Investigators Present Clinical Trial Data at 
Glasgow AIDS Meeting"
Business Wire (11/22/94)
     Data presented at the Second International Congress on Drug 
Therapy in HIV Infection in Glasgow, Scotland, show that Liposome
Technology's DOX-SL is a safe and effective therapy for patients 
with advanced AIDS-related Kaposi's sarcoma (KS).  DOX-SL is a 
long-circulating STEALTH liposome formulation of the anticancer 
agent doxorubicin hydrochloride.  Clinical data from a Phase II 
study of DOX-SL found that, at time of best response, 6.3 percent
of patients had a complete response to DOX-SL therapy, 74.4 
percent had a partial response, 18.5 percent had stable disease, 
and 0.8 percent had disease progression.  When presenting the 
data, Dr. Simon Stewart of St. Mary's Hospital in London 
concluded that DOX-SL appears to be effective palliative therapy 
for patients with HIV-related KS.  He also said that the drug is 
probably more effective and less toxic than Adria Laboratories' 
single agent Adriamycin and other anthracycline chemotherapy 
agents.
      
"Genesis House and Mercy Hospital to Hold 'Vigil Mass of Hope' to
Highlight World AIDS Day"
PR Newswire (11/21/94)
     A Vigil Mass of Hope, sponsored by Genesis House of the 
Archdiocese of Miami and Mercy Hospital, in conjunction with the 
South Florida World AIDS Day Coalition, will be held Nov. 30 to 
emphasize World AIDS Day on Dec. 1.  The Mass will be led by 
Archbishop Edward A. McCarthy with Monsignor Bryan O. Walsh of 
Catholic Community Services; Father Dan Dorrity, director of 
pastoral care at Genesis House; and additional clergy from the 
Archdiocese of Miami.  Those who attend the Mass will hear Sister
Elizabeth Anne Worley, Chairman of the Board of Trustees at Mercy
Hospital, speak about the effects of HIV on the church and on 
healthcare institutions.
      
"Tennis--Chris and Martina to Reunite for 1995 Legends Tour"
Reuters (11/21/94)
     Retired tennis stars Chris Evert and Martina Navratilova will 
take part in the women's Legends Tour next year, announced tour 
sponsor Virginia Slims on Monday.  The two will resume their 
legendary rivalry as they face off in a singles shoot-out 
competition each of the six weekends of the tour.  Players who 
have already signed up for the tour include Billie Jean King, 
Evonne Goolagong, Hana Mandlikova, and Tracy Austin.  Partial 
proceeds from the tour will benefit the National AIDS Fund in 
each community where the tour stops
      
"Behavioral Science in the AIDS Epidemic"
Lancet (11/12/94) Vol 344, No. 8933, P. 1312;  Watters, John K.
     There is growing evidence that public health measures, such as 
outreach programs for intravenous drug users and increased access
to sterile needles, have reduced the frequency of behaviors known
to transmit bloodborne diseases--including HIV, writes John K. 
Watters of the Institute for Health Policy Studies.  Despite such
successes, behavioral science is frequently regarded with 
skepticism by practitioners of biomedical science.  Behavioral 
science provides practical alternatives to actual 
experimentation.  According to Watters, the National Institutes 
of Health should, when restructuring its reviews of all grant 
applications, maintain a core of representation in areas 
including intervention, as well as ethnographic, epidemiological,
and demonstration research.  Thus, behavioral research would be 
protected in the short term.  In the long term future, behavioral
research will necessitate significant federal funding for 
graduate training programs, support for innovative research 
within the "new" NIH, and help from biomedical journals in 
disseminating the results.
      
"Efficient Neutralization of Primary Isolates of HIV-1 by a 
Recombinant Human Monoclonal Antibody"
Science (11/11/94) Vol. 266, No. 5187, P. 1024;  Burton, Dennis 
R.;  Pyati, Jayashree;  Koduri, Raju et al
     The inability of antibodies designed to neutralize primary 
isolates of HIV-1 has impeded the development of an HIV-1 
vaccine.  Burton et al created a recombinant human antibody to 
envelope glycoprotein gp120.  It was used to demonstrate that 
primary isolates are not refractory to antibody neutralization.  
The recombinant human antibody neutralized over 75 percent of the
primary isolates tested at concentrations that could be achieved 
by passive immunization.  The broad specificity and efficacy of 
the antibody indicates the conservation of a structural feature 
on gp120, which could be significant in the development of a 
vaccine.
      
"Red Hot+New"
Advocate (11/01/94) No. 667, P. 76;  Walters, Barry
     Two new benefit albums will raise funds for AIDS education and 
relief.  "Red Hot+Country" is a collection in which country music
stars sing songs or adopt styles that influenced their musical 
growth.  The albums includes Kathy Mattea, Dolly Parton, and Mary
Chapin Carpenter.  The second album, "Stolen Moments," crosses 
rappers with legends of jazz with pairs such as Me'shell 
Ndege-Ocello and Herbie Hancock.  Michael Franti, formerly of the
Disposable Heroes of Hiphoprisy, contributes the song 
"Positivity," which deals with the fears and frustrations of a 
man who is waiting for the results of his HIV test.
      
"A Cluster of Tuberculosis among Crack House Contacts in San 
Mateo County, California"
American Journal of Public Health (11/94) Vol. 84, No. 11, P. 
1834;  Leonhardt, Kathryn Kraft;  Gentile, Felicia;  Gilbert, 
Bradley P. et al
     A total of 89 people were diagnosed with tuberculosis (TB) in San
Mateo, Calif., in March 1992.  Fifteen percent, including 11 
children, had active pulmonary TB.  The contacts all either lived
in or visited one of two crack cocaine houses.  The index case, 
whose transient residence of several dwellings contributed to the
spread of the disease, was an HIV-infected male.  Public health 
workers used innovative methods, such as a mobile health van for 
TB screening, to help control the outbreak.  The outbreak might 
have been prevented if current recommendations for TB prevention 
in HIV-1 patients had been followed.  Continued special effort is
necessary to control the disease.
      
HOLIDAY NOTICE: The AIDS Daily Summary will not publish on
November 24-25 in observance of the Thanksgiving holidays.  
Publication will resume on Monday, November 28.
     